Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | RO5126766 |
Trade Name | |
Synonyms | Avutometinib|VS-6766|VS6766|VS 6766|CH5126766|CH-5126766|R-7304|RG-7304 |
Drug Descriptions |
RO5126766 (VS-6766) is dual RAF-MEK1/2 inhibitor with effectiveness against both BRAF and RAS mutated cells (PMID: 25422890). |
DrugClasses | MEK inhibitor (Pan) 23 MEK1 Inhibitor 25 MEK2 Inhibitor 23 RAF Inhibitor (Pan) 24 |
CAS Registry Number | 946128-88-7 |
NCIT ID | C80060 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abemaciclib + Fulvestrant + RO5126766 | Abemaciclib Fulvestrant RO5126766 | 0 | 1 |
Adagrasib + RO5126766 | Adagrasib RO5126766 | 0 | 1 |
Cetuximab + RO5126766 | Cetuximab RO5126766 | 0 | 1 |
Defactinib + Gemcitabine + Nab-paclitaxel + RO5126766 | Defactinib Gemcitabine Nab-paclitaxel RO5126766 | 0 | 1 |
Defactinib + RO5126766 | Defactinib RO5126766 | 0 | 6 |
Everolimus + RO5126766 | Everolimus RO5126766 | 1 | 1 |
RO5126766 | RO5126766 | 15 | 5 |
RO5126766 + Sotorasib | RO5126766 Sotorasib | 0 | 1 |
RO5126766 + VS-4718 | RO5126766 VS-4718 | 0 | 0 |